Ablynx has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody program. Ablynx will receive an upfront license fee of €5 million and up to €4 million in research funding during the initial three-year research term of the collaboration. If Novo Nordisk decides to exercise the option ...